EIKN Eikon Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1861123 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets45.6%
Debt / equity0.00x
Current ratio7.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $71.83M | $75.46M | $70.05M | $59.31M | $69.19M | $56.59M |
| SG&A expense | $18.73M | $17.93M | $17.29M | $15.44M | $40.45M | $14.80M |
| Operating income | -$90.55M | -$93.39M | -$87.34M | -$74.75M | -$109.64M | -$71.38M |
| Net income | -$86.11M | -$88.41M | -$82.96M | -$71.14M | -$105.21M | -$68.24M |
| EBITDA | -$85.55M | -$88.29M | -$82.12M | -$69.25M | -$105.44M | -$67.59M |
| EPS (basic) | -1.59 | -1.63 | -2.46 | -24.24 | -36.94 | -26.91 |
| EPS (diluted) | -1.59 | -1.63 | -2.46 | -24.24 | -36.94 | -26.91 |
| Weighted avg. shares (diluted) | 54.17M | 54.14M | 33.70M | 2.93M | 2.85M | 2.77M |
| Banking | ||||||
| Net interest income | $4.49M | $5.04M | $4.38M | $3.61M | $4.43M | $3.16M |
| Balance sheet | ||||||
| Cash & equivalents | $98.48M | $142.61M | $161.15M | $104.87M | $136.56M | $204.58M |
| Short-term investments | $363.24M | $388.56M | $351.03M | — | — | — |
| Current assets | $478.12M | $546.98M | $529.50M | — | — | — |
| PP&E, net | $128.56M | $133.07M | $138.07M | — | — | — |
| Total assets | $706.20M | $779.57M | $850.83M | — | — | — |
| Current liabilities | $66.27M | $55.30M | $45.06M | — | — | — |
| Total liabilities | $321.91M | $313.07M | $300.15M | — | — | — |
| Shareholders' equity | $384.29M | $466.50M | $550.67M | -$804.35M | -$737.50M | -$640.14M |
| Shares outstanding | 54.18M | 54.15M | 54.14M | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$69.19M | -$64.96M | -$89.80M | -$59.53M | -$32.74M | -$54.52M |
| Capital expenditure | $419,000 | $251,000 | $262,000 | $2.60M | $21.72M | $22.36M |
| Free cash flow | -$69.61M | -$65.21M | -$90.06M | -$62.14M | -$54.45M | -$76.88M |
| Investing cash flow | $24.94M | $46.43M | -$203.22M | $27.68M | -$35.88M | -$213.85M |
| Financing cash flow | $157,000 | $25,000 | $349.31M | $211,000 | $519,000 | $350.23M |
| Depreciation & amortization | $5.00M | $5.10M | $5.21M | $5.50M | $4.20M | $3.79M |
| Stock-based compensation | $3.75M | $4.22M | $2.78M | $3.99M | $7.21M | $2.97M |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.